Under the mutual agreement’s terms, Regencare will be fully in charge of product development, and Highfly will be responsible for the product distribution and sales.

Partnership will create the synergistic effects that maximize each company's advantages to boost sales while also fostering the creation of new products that address market needs.

Regencare Co., Ltd. (CEO Tae Sik Son) made a mutual agreement with the Highfly Co., Ltd. (CEO Jae Min Cho) for the development and sale of skin regeneration and wound care products on the April 12th at the Osong factory of Regencare Co., Ltd.  

Regencare Co., Ltd. will be responsible for product development under this agreement's terms. Highfly Co., Ltd. intends to sell products through distribution channels that include customers, hospitals, and already-secured pharmaceutical firms.

As a company specializing in wound care and skin regeneration medical devices, The Regencare is developing innovative burns removal and skin regeneration products through collaboration with burn specialists. Nowadays, they are aiming on identifying the correlation between skin wounds and calcium ion channels and developing new products.

Highfly Co., Ltd. has professional researchers in chemical synthesis and fermentation and is one of the leading companies in the field of Active Pharmaceutical Ingredient (API) that supplies raw materials to domestic and overseas pharmaceutical firms.

The two companies anticipate that this commercial partnership will maximize each company's advantages to boost sales while also fostering the creation of new products that address market demands. Regencare is anticipated to further enhance its product development research skills, and Highfly will be able to boost product sales by exploiting the established distribution network.

The Regencare official was quoted as saying, “We expect the cooperation between the two companies will lead to create more efficient products and the distribution network expansion with their technological advances. We are planning to maintain our cooperation to create the higher value in the medical field.”

[BIOTIMES=Reporter Sujin Kim] sjkimcap@biotimes.co.kr

Source : BIOTIMES (http://www.biotimes.co.kr)